KRCA 0008

Key Product Details

Product Description

KRCA 0008 is a potent Ack1 and anaplastic lymphoma kinase (ALK) dual inhibitor (IC₅₀ values are 4 and 12 nM respectively). Inhibits lung cancer H3122 cell proliferation (IC₅₀ = 80 nM). Attenuates H3122 cell xenograft tumor growth in mice. Orally bioavailable.

Product Specifications for KRCA 0008

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for KRCA 0008

The following data is based on the product molecular weight 609.12.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.64 mL	8.21 mL	16.42 mL
5 mM	0.33 mL	1.64 mL	3.28 mL
10 mM	0.16 mL	0.82 mL	1.64 mL
50 mM	0.03 mL	0.16 mL	0.33 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Lee ALK inhibitors of bis-ortho-alkoxy-para-piperazinesubstituted-pyrimidines and -triazines for cancer treatment. Arch.Pharm.Res. 2014 PMID: 24446111
• Park Novel bis-ortho-alkoxy-para-piperazinesubstituted-2,4-dianilinopyrimidines (KRCA-0008) as potent and selective ALK inhibitors for anticancer treatment. Bioorg.Med.Chem.Lett. 2013 PMID: 24095090

Product Documents for KRCA 0008